To address these problems, we have developed a separating MN drug delivery system consisting of GelMA and 5-FuA prodrug in response to endogenous stimuli (MMP2, MMP9 and ROS) to remodel the pathological microenvironment for HS treatment. The gene discussed is MMP2; the disease is histiocytic sarcoma.